Wholesale costs in the United States picked up sharply last month, signaling that price pressures are still evident in the economy even though inflation has tumbled from the peak levels it hit more than two years ago
U.S. applications for unemployment benefits jumped to their highest level in two months last week but remain low relative to historical standards
Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd) showed promise in the setting, offering encouragement as a late-stage trial progresses.
The orthopedic robotics developer Think Surgical has collected its third FDA clearance in as many months, with a specialized version of its knee replacement system designed to be paired with an implant from Zimmer Biomet.
Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data showing one of its other candidates induced 5% weight loss in a month.
AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 monoclonal antibody off track.
Relay Therapeutics has beaten its survival goal in a first-in-human breast cancer study, positioning the biotech to move into a pivotal trial that could establish its candidate as a challenger to AstraZeneca’s Truqap.
AstraZeneca has used artificial intelligence to devise a unique biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), hoping to differentiate the antibody-drug conjugate (ADC) from competitors while offering an explanation why the TROP2-directed therapy appears to work only in some non-small cell lung cancer (NSCLC) patients.
After overseeing the $4.1 billion sale of radiopharma player RayzeBio to Bristol Myers Squibb, biotech veteran Ken Song, M.D., didn’t take long to set up his next big venture. He is now chairman, president and CEO of Candid Therapeutics, which has debuted with a $370 million series A and a goal to dominate the T-cell engager market.
Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by the likes of Eli Lilly.
Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
‘Cooking with gas’: Regeneron sees its Opdualag rival as next big thing for treating solid tumors
IO Biotech’s vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
iTeos-GSK’s TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
Eli Lilly sells Life Sciences Studio lab to Arctoris, moving automation platform from San Diego to Oxford
Biolexis enters oral GLP-1 horse race with preclinical study showing small molecule reduced weight of obese mice
AstraZeneca steps out from Daiichi’s shadow, posting data on ADC rivals to AbbVie, Pfizer
Wall Street Rises to Turn a Dismal Week Into Just a Bad One
Tesla Recalling Almost 700,000 Vehicles Due to Tire Pressure Monitoring System Issue
